Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson
I M
IM
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Sweden.
Berntorp
E
E
D000293:Adolescent; D000327:Adsorption; D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D002836:Hemophilia B / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008875:Middle Aged; D013205:Staphylococcal Protein A
D001779:Blood Coagulation Factors; D007074:Immunoglobulin G; D013205:Staphylococcal Protein A; D003520:Cyclophosphamide; D005169:Factor VIII; D005164:Factor IX